Expect Bayer To Get Heat At FDA Advisory Panel Over Essure Adverse Events, Doc Training
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Obstetrics and Gynecology Devices Advisory Panel will discuss risk mitigation for pain, bleeding, and other events associated with its Essure sterility device on Sept. 24. Meanwhile, Bayer’s new summary for the meeting reveals several lawsuits were filed against it “making allegations [on] clinical trials and safety,” of Essure. A Citizen Petition says altered trial patient records and violations of adverse event reporting rules by Conceptus in 2011 invalidates its PMA.
You may also be interested in...
US FDA's Gottlieb Wants Safety Built Into New Medtech Products, But Budget Will Be Cut To Surveil Older Ones
President Trump's proposed budget cuts to the agency's post-market surveillance programs means that more "faulty" devices, such as St. Jude defibrillators and Bayer HealthCare's Essure birth control coils, will cause harm rather than be recalled, Rep. Rosa DeLauro said at a May 25 House Ag/FDA subpanel hearing. FDA Commissioner Scott Gottlieb told DeLauro the agency needs to supply "the right tools" to firms during device development so similarly flawed devices aren't put on the market, and he noted that the lifting of a hiring freeze at the agency earlier in the day would free the agency to work harder on such issues.
FDA Says Bayer's Response To Essure Investigation Satisfactory; Approves Product Label
FDA completed its investigation of a February 2015 trade complaint that charged clinical trial misconduct by Bayer HealthCare LLC for its controversial Essure permanently implanted birth control device, finding Bayer's response "satisfactory." The agency also approved amended labeling for the device.
FDA Investigating Attorney, Physician Beefs With Bayer’s Essure PMA
FDA is investigating claims in a Citizen’s Petition by plaintiff’s attorneys that patients’ responses to the Essure permanent birth control device were tampered with in the pivotal trial, and two gynecologists' complaints of inflated marketing.